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Risks of chronic metabolic acidosis in patients with chronic kid-
ney disease. Metabolic acidosis is associated with chronic renal
failure (CRF). Often, maintenance dialysis therapies are not
able to reverse this condition. The major systemic consequences
of chronic metabolic acidosis are increased protein catabolism,
decreased protein synthesis, and a negative protein balance that
improves after bicarbonate supplementation. Metabolic acido-
sis also induces insulin resistance and a decrease in the elevated
serum leptin levels associated with CRF. These three factors
may promote protein catabolism in maintenance dialysis pa-
tients. Available data suggest that metabolic acidosis is both
catabolic and anti-anabolic. Several clinical studies have shown
that correction of metabolic acidosis in maintenance dialysis
patients is associated with modest improvements in nutritional
status. Preliminary evidence indicates that metabolic acidosis
may play a role in b2-microglobulin accumulation, as well as
the hypertriglyceridemia seen in renal failure. Interventional
studies for metabolic acidosis have yielded inconsistent results
in CRF and maintenance hemodialysis patients. In chronic peri-
toneal dialysis patients, the mitigation of acidemia appears more
consistently to improve nutritional status and reduce hospi-
talizations. Large-scale, prospective, randomized interventional
studies are needed to ascertain the potential benefits of correct-
ing acidemia in maintenance hemodialysis patients. To avoid
adverse events, an aggressive management approach is neces-
sary to correct metabolic acidosis. Clinicians should attempt
to adhere to the National Kidney Foundation Kidney Disease
Outcome Quality Initiative (K/DOQI) guidelines for mainte-
nance dialysis patients. The guidelines recommend maintenance
of serum bicarbonate levels at 22 mEq/L or greater.
Advanced chronic renal failure (CRF) often results in
metabolic acidosis, a process that promotes an increase in
hydrogen ions in the body. Metabolic acidosis in CRF is
the result of a decreased ability to excrete nonvolatile acid
and the reduced renal synthesis of bicarbonate. Mainte-
nance dialysis therapies are often not able to completely
correct the base deficit. In patients on maintenance dial-
ysis, severe metabolic acidosis is associated with an in-
creased relative risk for death. However, many epidemi-
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ologic studies on patients undergoing maintenance dialy-
sis have indicated a paradoxically inverse association be-
tween mildly decreased serum bicarbonate and improved
markers of protein-energy nutritional state. This review
will discuss the risk of chronic metabolic acidosis in pa-
tients with CRF, with regard to its effect on nutritional
status and bone metabolism.
METABOLIC ACIDOSIS
Severe chronic metabolic acidosis (i.e., the presence of
excess hydrogen ions in blood) has two well-recognized
major systemic consequences. First, metabolic acidosis,
or acidemia, induces increased protein catabolism, de-
creased protein synthesis, and negative nitrogen and
total body protein balance, which improve upon bi-
carbonate supplementation. Second, metabolic acidosis
causes physicochemical dissolution of bone and cell-
mediated bone resorption (inhibition of osteoblast and
stimulation of osteoclast function).
To avoid a misdiagnosis of metabolic acidosis, it is im-
portant to handle blood specimens with utmost care. Un-
derfilling of sample tubes may lead to evanescence of car-
bon dioxide, which results in falsely low values [1]. The
transportation of blood specimens—particularly via air—
to distant laboratories, could lead to loss of total CO2 and
overestimation of the magnitude of acidosis. The mean
CO2 level of shipped blood samples is 5 mEq/L lower
than that of blood samples processed immediately [2].
Also, serum bicarbonate measurements may suggest an
inaccurately increased bicarbonate level, because the to-
tal serum CO2 measurement usually overestimates the
serum bicarbonate concentration. Thus, it is important
to exercise caution when interpreting serum chemistry
measurements that indicate metabolic acidosis in main-
tenance dialysis patients.
METABOLIC ACIDOSIS AND NUTRITION
In 1931, Lyon et al were the first investigators to sug-
gest a potential link between metabolic acidosis and the
nutritional status of patients with CRF (reviewed by
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Fig. 1. Nitrogen and potassium balance in 6 nondialyzed uremic pa-
tients pre- and postsupplementation with sodium bicarbonate. (From
[4]).
Mehrotra et al [3]). Additional literature has subse-
quently suggested that metabolic acidosis may play an
important role in the pathogenesis of nutritional ab-
normalities associated with uremia. Increased protein
catabolism, decreased protein synthesis, increased insulin
resistance, inflammation, and reduced serum leptin levels
are 5 potential mechanisms by which metabolic acidosis
could contribute to these nutritional abnormalities.
Catabolic effects: The ubiquitin-proteosome system
Multiple studies suggest that metabolic acidosis could
cause negative nitrogen balance in CRF patients, as well
as in healthy individuals. Papadoyannakis et al measured
nitrogen and potassium levels in 6 nondialyzed uremic in-
dividuals before and after supplementation with sodium
chloride and sodium bicarbonate [4]. A significant de-
crease in blood urea nitrogen and a positive nitrogen and
potassium balance were detected during bicarbonate sup-
plementation (Fig. 1).
There are several studies that have investigated the
effect of metabolic acidosis on protein metabolism [5–
8], and all but one study [5] have shown that metabolic
acidosis promotes proteolysis. In general, treatment to
increase blood pH from acidemic levels to normal levels
resulted in a decrease in protein degradation. Table 1
summarizes data from these studies, obtained from
patients with varying stages of renal failure [5–8].
Researchers believe that metabolic acidosis promotes
protein degradation by stimulation of the ubiquitin-
proteosome system, through which proteins are gener-
ally targeted for digestion to peptides and amino acids.
Acidemia causes an increase in gene transcription for the
proteosome and increased ubiquitin synthesis. Increased
activity of the proteolytic enzyme caspase-3 and the ATP-
dependent ubiquitin-proteosome pathway has been im-
plicated in mediating the catabolic effects of metabolic
acidosis in CRF in both human and animal model sys-
tems [9]. For example, Bailey et al observed that in uremic
rats metabolic acidemia is associated with increased pro-
tein degradation and amino acid oxidation. The mRNA
for proteosome and ubiquitin in skeletal muscle cells was
also found to be elevated. The addition of sodium bicar-
bonate to the diet of these animals resulted in a reversal
of protein degradation [10].
Pickering et al made a similar observation in studies
of muscle mRNA from patients with CRF. A significant
decrease in ubiquitin mRNA abundance was seen after 4
weeks of bicarbonate treatment [11]. In addition, studies
in isolated rat skeletal muscles exposed to an inhibitor of
the proteosome, or depleted of ATP, in the presence of
metabolic acidosis, have demonstrated that the increased
protein degradation induced by metabolic acidemia was
abolished. These observations indicate that the ubiquitin-
proteosome pathway is an important mechanism for pro-
tein catabolism associated with metabolic acidemia.
Catabolic effects: Branched-chain amino
acids metabolism
Branched-chain amino acids (BCAA) are often altered
in pathologic conditions associated with metabolic acido-
sis. Studies in rats, as well as in isolated skeletal muscle
cells, have shown that acidosis stimulates the breakdown
of BCAA. Metabolic acidosis increases the gene tran-
scription for an enzyme called branched chain keto-acid
dehydrogenase (BCKAD). This enzyme degrades 3 es-
sential branched chain amino acids: leucine, isoleucine,
and valine [12].
Lower levels of plasma and muscle BCAA are re-
ported in patients undergoing maintenance dialysis ther-
apy, as well as in animal models of metabolic acidosis
[13, 14]. Correction of metabolic acidosis in patients on
maintenance hemodialysis results in an increase in the
plasma BCAA levels, as seen in Figure 2 [14]. These
observations suggest that patients suffering from CRF
associated with metabolic acidosis experience increased
activity of BCKAD, which causes increased catabolism
of BCAA. Thus, increased activity of caspase-3, the
ATP-dependent ubiquitin-proteasome and BCKAD ap-
pears to contribute significantly to the negative nitro-
gen balance observed in uremic patients with metabolic
acidemia.
Anti-anabolic effects of metabolic acidosis
Metabolic acidosis possibly may decrease protein syn-
thesis and produce anti-anabolic effects. Cell culture stud-
ies of myocytes in an acidic medium have shown reduced
protein synthesis, and some studies of metabolic acido-
sis in humans demonstrate analogous results. Induction of
metabolic acidosis in normal individuals with ammonium
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Table 1. Improvement in metabolic acidosis and protein turnover: Summary of controlled studies in CRF patients
First No. of Stage of Baseline Final Protein Protein Amino acid
author subjects renal failure pH pH synthesis degradation oxidation
Reaich [6] 9 Nondialyzed 7.31 7.38 Decreased Decreased Decreased
Graham [7] 7 CPD 7.39 7.41 Decreased Decreased No change
Graham [8] 6 MHD 7.36 7.4 Decreased Decreased No change
Lim [5] 8 Nondialyzed 7.29 7.39 No change No change Increased
Abbreviations: CPD, chronic peritoneal dialysis; MHD, maintenance hemodialysis.
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Fig. 2. Branched chain amino acid levels measured in 9 hemodialysis
patients before and after 6 months of bicarbonate treatment. A signifi-
cant increase in the concentration of valine, leucine, and isoleucine was
seen on correction of the metabolic acidosis. (From [4]).
chloride caused a significant reduction in the fractional
synthetic rate of muscle protein, while the fractional and
absolute rate of albumin synthesis remained unchanged
[15]. Conversely, in another study, chronic ammonium
chloride-induced metabolic acidosis was reported to sig-
nificantly reduce the fractional synthetic rate of albumin
[16]. In light of these conflicting findings, the applicabil-
ity of these observations to metabolic acidosis in CRF is
uncertain, and additional data are needed to determine
the effects of metabolic acidosis associated with CRF on
protein synthesis. Figure 3 summarizes the mechanisms
by which metabolic acidosis could induce protein energy
malnutrition [3].
The anti-anabolic effects of ammonium chloride-
induced metabolic acidosis could arise from possible al-
terations in 1 or more of 4 hormonal systems. First,
metabolic acidosis could reduce the release of growth
hormone. Experimental data suggest that peripheral re-
sistance to growth hormone could result from metabolic
acidosis. Second, metabolic acidemia may induce insulin
resistance (see below). Third, in both human subjects and
animal studies, plasma levels of insulin-like growth factor
(IGF) and the hepatic content of IGF-1 mRNA, are sig-
nificantly reduced in metabolic acidosis. Fourth, the an-
abolic effects of thyroid hormone and the reduced thyroid
function induced by metabolic acidosis could contribute
to decreased synthesis of muscle protein.
A modest, though significant, increase in the levels
of thyroid-stimulating hormone has been reported in
acute metabolic acidosis, without any change in the lev-
els of free triiodothyronine (T3). Chronic acidosis in
human subjects, however, is associated with significantly
reduced T3 levels, with no change in the levels of thyroid-
stimulating hormone. Additional studies are required to
determine the relative contributions of these hormonal
systems to the altered anabolic and catabolic pathways in
CRF (reviewed by Mehrotra et al in [3]). In sum, these
data suggest that metabolic acidosis has both catabolic
and anti-anabolic effects on nutritional status of patients
with CRF. Figure 3 summarizes the catabolic and anti-
anabolic effects of metabolic acidosis.
Hormonal triggers in metabolic acidosis
Despite recent progress made in understanding the
molecular mechanisms of proteolysis in the setting of
metabolic acidosis, other triggers that activate these path-
ways are not fully understood.
Cortisol
Ammonium chloride-induced metabolic acidosis in
adrenalectomized rats does not cause induction of pro-
tein degradation, or an increase in the gene expression
of BCKAD or its activity, and does not lead to increases
in mRNA for the ubiquitin-proteosome system in mus-
cle. Additionally, in rats with acidotic experimental renal
failure, the urinary excretion of corticosterone was sig-
nificantly elevated when compared with control animals.
These observations implicate glucocorticoids as a major
factor necessary for the induction of the catabolic path-
ways in metabolic acidosis. A direct, positive correlation
of muscle protein degradation with plasma levels of cor-
tisol, and a negative correlation with serum bicarbonate
levels, suggests that a combination of acidosis and glu-
cocorticoids may be needed to stimulate muscle protein
degradation. However, other investigators have not been
able to demonstrate increased concentrations of cortisol
in the setting of chronic metabolic acidosis (reviewed by
Mehrotra et al in [3]). Hence, the involvement of corticos-
teroids in stimulating skeletal muscle protein degradation
needs further investigation.
Insulin resistance
It has been suggested that insulin resistance, a com-
plication of CRF, plays a role in the activation of the
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Fig. 3. Mechanisms by which metabolic acidosis may induce protein energy malnutrition. (From [3]).
ubiquitin-proteosome system. Administration of insulin
to rats with diabetic ketosis eliminated excess prote-
olysis, as well as the increased ubiquitin mRNA [17].
Additionally, insulin-stimulated phosphorylation of the
insulin-receptor substrate-1 (IRS-1) phosphoinostitol-3
kinase (PI-3 kinase) activity is significantly reduced in
rats with renal failure. The activation of the ubiquitin-
proteosome pathway and muscle protein degradation are
thought to result from suppressed PI-3 kinase activity.
Thus, glucocorticoids and low insulin levels may act in
tandem to activate the ubiquitin-proteosome pathway.
Leptin
Leptin, a protein encoded by the obese (ob) gene, is
involved with food intake, energy expenditure, and body
weight. It has been studied as a potential mediator of
protein energy malnutrition. Circulating leptin is partly
cleared by the kidney, and is reported to increase 3-fold
in individuals with CRF compared with healthy controls
with similar body mass index [18]. Metabolic acidosis and
hyperleptinemia are 2 common clinical findings in pa-
tients with CRF. In animal studies, decreased leptin secre-
tion has been observed in adipocytes exposed to relatively
acidic environments (pH 7.1). Sodium bicarbonate treat-
ment of rats with renal failure showed significantly re-
duced leptin levels, compared with untreated rats. Plasma
leptin concentrations were also lower in patients with di-
abetic ketoacidosis compared with healthy individuals.
Initiation of insulin therapy resulted in increased leptin
levels. Correcting the metabolic acidosis in nondialyzed
individuals with CRF resulted in increased serum leptin
levels [19]. However, Kokot et al were unable to demon-
strate a correlation between blood hydrogen concentra-
tions and serum leptin levels in a cross-sectional study of
94 patients on maintenance hemodialysis [20]. The study
did, however, reveal a trend toward progressively lower
median leptin concentrations with progressively higher
blood hydrogen concentrations. Because increased serum
leptin levels are associated with weight loss, a decrease
in serum leptin levels could adaptively ameliorate the
catabolic effects of metabolic acidosis.
INFLAMMATION AND METABOLIC ACIDOSIS
Emerging evidence suggests that metabolic acido-
sis may induce chronic inflammation (reviewed by
Mehrotra et al [3]). Increased production of a key inflam-
matory cytokine—tumor necrosis factor a (TNFa)—by
peritoneal macrophages incubated in an acidic cell cul-
ture medium suggests a potential link between the in-
flammatory process and metabolic acidosis. Two recent
studies have analyzed the link between metabolic acidosis
and inflammation. In the first study, markers of inflamma-
tion, serum C-reactive protein (CRP) and interleukin-6
(IL-6), were evaluated in maintenance hemodialysis pa-
tients. No significant difference in serum levels of CRP
or IL-6 was seen in 3 groups of patients subdivided on
the basis of their serum CO2 levels [21]. In the second
study, correction of metabolic acidosis in 8 chronic peri-
toneal dialysis patients was associated with significantly
reduced levels of TNFa [11]. It is important to mention
that the acidic pH in these studies is 7.39 and the alka-
line pH is 7.42, and metabolic changes are seen within
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Fig. 4. The various mechanisms by which metabolic acidosis may contribute to bone disease. (From [3]).
this narrow pH range. These observations raise an im-
portant question as to whether there is an optimal pH for
maintaining healthy nutritional status. In various studies,
an increase in the pH from 7.23 to 7.7 of the cell culture
medium results in a progressive increase in the rate of pro-
tein synthesis. Interestingly, at increased pH levels (pH
>7.4), protein synthesis by skeletal muscles is enhanced,
possibly suggesting an increased pH to be optimal for
anabolism.
METABOLIC ACIDOSIS AND BONE DISEASE
Metabolic acidosis exerts multiple effects on bone. It
causes the physicochemical dissolution of bone and cell-
mediated bone resorption through the inhibition of os-
teoblast activity and stimulation of osteoclast function.
These events are associated with a loss of calcium and
phosphorus from the bone. Metabolic acidosis stimulates
osteoblasts to release prostaglandins. This stimulates os-
teoclast function and inhibits osteoblast activity. Gluco-
corticoids can inhibit the production of prostaglandins by
osteoblasts.
Metabolic acidosis is also associated with a decrease in
the content of bone bicarbonate. Additionally, bicarbon-
ate supplementation in postmenopausal women is associ-
ated with decreases in urinary calcium, phosphorus, and
increased osteocalcin levels, indicating a beneficial effect.
Figure 4 shows the mechanisms relating metabolic aci-
dosis with bone disease [3]. These observations suggest
that uncorrected metabolic acidosis has adverse conse-
quences on bone anatomy and physiology.
METABOLIC ACIDOSIS AND SECONDARY
HYPERPARATHYROIDISM
Metabolic acidosis is probably also associated with
worsening of secondary hyperparathyroidism. Metabolic
acidosis may decrease the sensitivity of PTH secretion
to elevated ionized calcium [22]. The effect of metabolic
acidemia on serum PTH level is rather variable [23]. On
the other hand, Lefebvre et al studied the role of aci-
dosis on hemodialysis osteodystrophy in a group of 21
patients dialyzed with varying amounts of HCO3 over an
18-month interval [24]. These data show no increase in
serum PTH levels in patients treated with higher dialysate
bicarbonate. However, serum PTH levels increased sig-
nificantly in patients with persistent metabolic acidosis
who were treated with standard dialysate bicarbonate.
Additionally, other investigators report a decrease in
serum PTH levels after correcting metabolic acidosis in
maintenance hemodialysis patients.
The combination of metabolic acidemia and elevated
serum levels of parathyroid hormone, such as is found in
patients with CRF, leads to a far greater efflux of Ca com-
pared with either metabolic acidemia or hyperparathy-
roidism alone (reviewed in Bushinsky and Frick [25] and
Bushinsky and Nilsson [26]). Correction of metabolic
acidemia improves bone mineralization and histology
in maintenance hemodialysis patients. Thus, the avail-
able data suggest that metabolic acidosis may lead to
worsening of secondary hyperparathyroidism. Metabolic
acidemia also reduces 1-alphahydroxylase activity in re-
nal tubules of rats, but the effects on serum levels of 1,25-
dihydroxycholecalciferol, the metabolic product of this
enzyme, are more difficult to ascertain [3, 27].
OTHER CLINICAL AND METABOLIC
ALTERATIONS OF METABOLIC ACIDOSIS
Preliminary evidence also suggests that metabolic
acidosis, in addition to its effects on protein and
bone metabolism, may play a role in the accumula-
tion of b-2 microglobulin, hypertriglyceridemia, malaise,
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hypotension, and in the resistance to catecholamines [28,
29]. The small subunit of the MHC class I molecule, b-2
microglobulin, is located on the cell membrane of many
cells, including lymphocytes. Small amounts of b-2 mi-
croglobulin are found in serum, plasma, and urine of nor-
mal individuals, while elevated levels are often seen in the
plasma and urine of patients with renal failure and kid-
ney transplants. Studies using cell cultures as well as CRF
patients have shown increased mRNA, as well as serum
levels of b-2 microglobulin (reviewed by Mehrotra et al
in [3]).
NATIONAL KIDNEY FOUNDATION KIDNEY
DISEASE OUTCOME QUALITY INITIATIVE
GUIDELINES FOR NUTRITION IN PATIENTS
WITH CRF
The K/DQOI has developed guidelines for patients
with CRF. One is the monthly measuring of serum bi-
carbonate levels in maintenance dialysis patients. It is
recommended that the predialysis or stabilized serum bi-
carbonate should be maintained at ≥22 mEq/L in these
individuals [30]. In patients with chronic kidney disease,
stages 3, 4, and 5, the serum levels of total CO2 also should
be maintained at ≥22 mEq/L [31]. To achieve this goal,
supplemental alkali should be given as required.
CONCLUSION
Uncorrected metabolic acidosis is detrimental to the
nutritional status, may aggravate bone disease and, thus,
may impact the overall health of maintenance hemodial-
ysis patients. A small, persistent decrease in the rate
of protein synthesis, or increase in protein degradation,
could result in a substantial loss of muscle mass and de-
velopment of more severe chronic bone disease, such
as that seen in patients with CRF and end-stage kid-
ney disease. The caspase-3, ubiquitin-proteosome sys-
tem targets proteins for degradation and may contribute
to protein catabolism and negative protein balance in
CRF. However, additional catabolic signals may con-
tribute to this process. New information that identi-
fies mechanisms involved in the complex pathways of
protein catabolism is crucial with regard to developing
new therapies to prevent the loss of muscle mass in
CRF. Based on currently available data, clinicians should
adhere to the K/DOQI guidelines for maintenance
dialysis patients and maintain predialysis bicarbonate
concentrations ≥22 mEq/L. Large-scale, prospective,
randomized interventional studies are needed to as-
certain the potential benefits of correcting acidemia in
both maintenance hemodialysis and chronic peritoneal
dialysis patients. An aggressive approach to correcting
metabolic acidosis seems indicated to help to prevent the
multiple adverse consequences of this condition.
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